NCT02107261View on ClinicalTrials.gov

Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Dystonia
Interventions
DRUG

incobotulinumtoxin A

Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.

DRUG

Placebo

matching placebo

Trial Locations (2)

10017

NYU Langone Health, New York

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

Merz North America, Inc.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT02107261 - Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand | Biotech Hunter | Biotech Hunter